Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 72

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 72
---
 commencing July 24, 2024 through December 31, 2024, representing an
increase of $1,050 thousand, or 1,019.4%, compared to Predecessor’s $103 thousand for the same period. The increase was primarily
attributable to Successor’s share-based payment compensation, Successor’s salaries and related expenses and Successor’s
professional services for such period compared to no such expenses in the Predecessor for the same period.

<div align='center'>42</div>

Operating Loss

As a result of the foregoing, Successor’s
and Predecessor’s operating loss totaled $2,149 thousand for the period commencing July 23, 2024 through December 31, 2024, representing
an increase of $1,376 thousand, or 178.0%, compared to Predecessor’s $773 thousand for the same period.

Financing expense (income), Net

Successor’s and Predecessor’s recognized
financing income, net of $65 thousand for the period commencing July 24, 2024 through December 31, 2024, representing a decrease of $75
thousand, or 750.0%, compared to Predecessor’s finance expense, net of $10 thousand for the same period. The decrease in finance
expenses was primarily attributable to Successor’s interest income from deposit and Successor’s higher exchange rate differences
between the U.S. dollar and the New Israeli Shekel.

Net and Comprehensive Loss

As a result of the foregoing, Successor’s
and Predecessor’s loss totaled $2,084 thousand for the period commencing July 24, 2024 through December 31, 2024, representing
an increase of $1,301 thousand, or 166.1%, compared to Predecessor’s $783 thousand for the same period.

Comparison of the period commencing January 1, 2024 through July 23, 2024 (Successor and Predecessor) to the period commencing January 1, 2024 through July 23, 2024 (Predecessor)

The following table is data derived from the
Consolidated Statement of Operations (in thousands) and the discussions that follow are in approximate amounts

|                                     |     |         Non-GAAP Combined |       |   |     |                      |       |
|                                     |     | Successor and Predecessor |       |   |     |